Actively Recruiting
Phase 1 Study of Oral DO-2 for Safety and Pharmacokinetics in Adults with Advanced or Refractory Solid Tumors Including Non-Small Cell Lung Cancer with MET Mutation
Led by DeuterOncology · Updated on 2026-04-03
55
Participants Needed
13
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating DO-2, an investigational oral drug, in patients with advanced or treatment-resistant solid tumors that show MET gene changes and have no approved treatment options available. This first-in-human, open-label Phase 1 study includes two parts an initial dose escalation phase and an ongoing expansion phase focused on non-small-cell lung cancer NSCLC with a specific MET mutation. In the first part, patients receive increasing doses of DO-2 to determine safety and appropriate dosing using a stepwise method depending on side effects. In the second part, up to 30 patients with advanced NSCLC carrying the MET exon 14 skipping mutation, who have exhausted standard therapies, receive DO-2 orally once daily in 28-day cycles at the selected dose. Participants will be monitored for side effects and treatment-related adverse events over about 12 months. Researchers will assess tumor response using established criteria and track how long any response lasts, disease control, progression-free survival, and overall survival. Safety and drug behavior in the body will also be closely watched throughout the study period.
CONDITIONS
Brief Title
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
Research Team
T
Timothy Perera, PhD
D
Desirée Kanters
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here